CD33-NKE

N/A

Report date: 2024/06/28 10:46:33

Base Information

Drug NameCD33-NKE

Drug Alias NameCD33-natural killer cell engager (Bristol-Myers Squibb)CD33-NKE

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionMyeloid cell surface antigen CD33 modulators

TargetsMyeloid cell surface antigen CD33

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBristol-Myers Squibb Company

China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Company

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A